About: Molecular aspects of MERS-CoV

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Molecular aspects of MERS-CoV Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Molecular aspects of MERS-CoV
Creator	Al-Ahmed, Shamsah Al-Tawfiq, Jaffar Bazzi, Ali Rabaan, Ali
Source	Medline; PMC
abstract	Middle East respiratory syndrome coronavirus (MERS-CoV) is a betacoronavirus which can cause acute respiratory distress in humans and is associated with a relatively high mortality rate. Since it was first identified in a patient who died in a Jeddah hospital in 2012, the World Health Organization has been notified of 1735 laboratory-confirmed cases from 27 countries, including 628 deaths. Most cases have occurred in Saudi Arabia. MERS-CoVancestors may be found in OldWorld bats of the Vespertilionidae family. After a proposed bat to camel switching event, transmission of MERS-CoV to humans is likely to have been the result of multiple zoonotic transfers from dromedary camels. Human-to-human transmission appears to require close contact with infected persons, with outbreaks mainly occurring in hospital environments. Outbreaks have been associated with inadequate infection prevention and control implementation, resulting in recommendations on basic and more advanced infection prevention and control measures by the World Health Organization, and issuing of government guidelines based on these recommendations in affected countries including Saudi Arabia. Evolutionary changes in the virus, particularly in the viral spike protein which mediates virus-host cell contact may potentially increase transmission of this virus. Efforts are on-going to identify specific evidence-based therapies or vaccines. The broad-spectrum antiviral nitazoxanide has been shown to have in vitro activity against MERS-CoV. Synthetic peptides and candidate vaccines based on regions of the spike protein have shown promise in rodent and non-human primate models. GLS-5300, a prophylactic DNA-plasmid vaccine encoding S protein, is the first MERS-CoV vaccine to be tested in humans, while monoclonal antibody, m336 has given promising results in animal models and has potential for use in outbreak situations.
has issue date	2017-05-13(xsd:dateTime)
bibo:doi	10.1007/s11684-017-0521-z
bibo:pmid	28500431
has license	no-cc
sha1sum (hex)	2e18ad30b21c44e8b5e1f54fc015ce512c19e1a7
schema:url	https://doi.org/10.1007/s11684-017-0521-z
resource representing a document's title	Molecular aspects of MERS-CoV
has PubMed Central identifier	PMC7089120
has PubMed identifier	28500431
schema:publication	Front Med
resource representing a document's body	covid:2e18ad30b21c44e8b5e1f54fc015ce512c19e1a7#body_text
is schema:about of	named entity 'humans' named entity 'high' named entity 'activity' named entity 'camel' named entity 'infection prevention' named entity 'aspects' named entity 'BATS' named entity 'SPIKE PROTEIN' named entity 'HUMANS' named entity 'RESULT' named entity 'PATIENT' named entity 'LABORATORY' named entity 'ANCESTORS' named entity 'CASES' named entity 'OUTBREAKS' named entity 'ASSOCIATED WITH' named entity 'TRANSFERS' named entity 'VESPERTILIONIDAE' named entity 'IS A' named entity 'OLD' named entity 'PROTEIN ' named entity 'THESE' named entity 'MAY BE' named entity 'ANIMAL MODELS ' named entity 'PREVENTION AND CONTROL' named entity 'TESTED' named entity 'HOSPITAL' named entity 'HIGH' named entity 'ZOONOTIC' named entity 'MONOCLONAL ANTIBODY' named entity 'MERS-COV' named entity 'MOLECULAR' named entity 'INFECTION PREVENTION' named entity 'PERSONS' named entity 'MORTALITY RATE' named entity 'RESULTS' named entity 'REGIONS' named entity 'THERAPIES' named entity 'CANDIDATE' named entity 'ADVANCED' named entity 'MULTIPLE' named entity 'BASIC' named entity 'MEASURES' named entity 'GUIDELINES ' named entity 'S PROTEIN' named entity 'HUMAN' named entity 'FAMILY' named entity 'ACUTE RESPIRATORY DISTRESS' named entity 'INFECTED' named entity 'ENCODING' named entity 'CHANGES' named entity 'DIED' named entity 'NITAZOXANIDE' named entity 'RESULTING IN' named entity 'WORLD' named entity 'IDENTIFIED' named entity 'BASED' named entity 'EVIDENCE' named entity 'SPECTRUM' named entity 'TO IDENTIFY' named entity 'CAUSE' named entity 'CONTACT WITH' named entity 'INCLUDING' named entity 'ISSUING' named entity 'RECOMMENDATIONS' named entity 'MODELS' named entity 'COUNTRIES' named entity 'PROPHYLACTIC' named entity 'IMPLEMENTATION' named entity 'MEDIATES' named entity 'OCCURRED' named entity 'WORLD HEALTH ORGANIZATION' named entity 'PROMISE' named entity 'SPECIFIC' named entity 'BETACORONAVIRUS' named entity 'VACCINES' named entity 'VIRUS' named entity 'CAMELS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software